Circulating Mutant BRAF DNA Detection via PCR Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring melanoma lack effective tools for early detection, prognosis, and treatment stratification, particularly for metastatic disease, due to the absence of reliable tumor markers and invasive diagnostic procedures.
Innovation Solution
A novel method for detecting circulating mutant BRAF DNA in peripheral blood using PCR amplification with specific primers, allowing for non-invasive diagnosis, prognosis, and monitoring of melanoma, enabling the assessment of treatment efficacy and mutation status without the need for biopsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive diagnostic procedures are used to detect melanoma, then diagnostic accuracy is improved, but patient morbidity and procedural complexity increase
Solution Approach 1:
The patent uses circulating tumor DNA (ctDNA) as an intermediary biomarker to detect melanoma metastasis. Instead of directly examining tissue through invasive biopsies, the method detects mutant BRAF DNA sequences in peripheral blood, which serves as a non-invasive proxy for tumor presence and mutation status, thereby maintaining diagnostic accuracy while eliminating procedural morbidity
Solution Approach 2:
The patent replaces mechanical tissue sampling (biopsy) with molecular detection in liquid biopsy. The mechanical invasion of tissue is substituted by detecting circulating DNA molecules in blood, transforming a mechanically invasive procedure into a minimally invasive blood draw followed by molecular analysis
2Reliability
If tumor markers are developed for early detection, then early diagnosis capability is improved, but the complexity of marker identification and validation increases
Solution Approach 1:
The patent focuses on detecting specific parameter changes - the presence of mutant BRAF DNA sequences (particularly V600E mutation) in circulating tumor DNA. By targeting specific genetic mutations known to be prevalent in melanoma, the method simplifies the marker identification process while maintaining high reliability for early detection and treatment stratification
3Ease of operation
If circulating tumor DNA detection is implemented, then non-invasive monitoring is achieved, but detection sensitivity for low tumor burden must be maintained
Solution Approach 1:
The patent employs preliminary enrichment and concentration steps to isolate and concentrate circulating tumor DNA from peripheral blood before analysis. This preliminary action increases the concentration of rare mutant DNA molecules, ensuring that even low tumor burden states can be detected with high sensitivity while maintaining the non-invasive nature of blood sampling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of metastatic melanoma, predicts treatment outcomes, and determines the suitability of BRAF inhibitors, providing a non-invasive and accurate means for monitoring disease progression and response to therapy.
Implementation Method 1
A method for detecting the presence of circulating mutant BRAF DNA in peripheral blood
Data Source
AI summary
The present invention relates to a method for detecting the presence of circulating mutant BRAF DNA, which may be present in circulating melanoma cells or as DNA shed from tumor cells. Methods, compositions and kits which employ one or more sets of BRAF mutant specific primer pairs for detection of circulating mutant BRAF DNA are presented. Also provided are methods for diagnosing and/or determining stage/progression of a melanoma in a mammal based on detection of a BRAF mutant nucleic acid sequence. Such methods are also well suited to monitoring disease activity in patients with active disease or those in remission.